Difference between revisions of "Small cell lung cancer - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
m (→Observation) |
||
Line 72: | Line 72: | ||
|[[Small_cell_lung_cancer#Sunitinib_monotherapy|Sunitinib]] | |[[Small_cell_lung_cancer#Sunitinib_monotherapy|Sunitinib]] | ||
| style="background-color:#fc8d59" |Seems to have inferior PFS | | style="background-color:#fc8d59" |Seems to have inferior PFS | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/j.lungcan.2019.06.011 Santo et al. 2019 (G04.2011)] | ||
+ | |2012-2016 | ||
+ | | style="background-color:#1a9851" |Phase III (C) | ||
+ | |Lanreotide | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
|} | |} | ||
''No further treatment.'' | ''No further treatment.'' | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *'''G04.2011:''' Somatostatin receptor positivity at diagnosis | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*ECOG E7593: [[Small_cell_lung_cancer#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] x 4 | *ECOG E7593: [[Small_cell_lung_cancer#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] x 4 | ||
*CALGB 30504: [[Small_cell_lung_cancer#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]] or [[Small_cell_lung_cancer#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] for 4 to 6 cycles | *CALGB 30504: [[Small_cell_lung_cancer#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]] or [[Small_cell_lung_cancer#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] for 4 to 6 cycles | ||
+ | *G04.2011: [[Small_cell_lung_cancer#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]] or [[Small_cell_lung_cancer#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] | ||
===References=== | ===References=== | ||
Line 84: | Line 93: | ||
# '''ECOG E7593:''' Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. [https://doi.org/10.1200/JCO.2001.19.8.2114 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11304763 PubMed] | # '''ECOG E7593:''' Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. [https://doi.org/10.1200/JCO.2001.19.8.2114 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11304763 PubMed] | ||
# Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. [https://doi.org/10.1093/annonc/mdf014 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11863118 PubMed] | # Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. [https://doi.org/10.1093/annonc/mdf014 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11863118 PubMed] | ||
− | # '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [https://doi.org/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed] | + | # '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [https://doi.org/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed] NCT00453154 |
+ | # '''G04.2011:''' Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer). Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer. 2019 Aug;134:121-126. Epub 2019 Jun 11. [https://doi.org/10.1016/j.lungcan.2019.06.011 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31319970 PubMed] EudraCT 2011-005730-20 | ||
==Placebo== | ==Placebo== |
Revision as of 01:04, 12 October 2020
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main SCLC page for current regimens.
Limited stage, consolidation after upfront therapy
Observation
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelly et al. 1995 (SWOG 8812) | 1989-1991 | Phase III (C) | IFN alfa-2a | Did not meet primary endpoint of OS |
No further treatment.
Preceding treatment
- Chemoradiotherapy
References
- SWOG 8812: Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, Livingston R. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec;13(12):2924-30. link to original article PubMed
Extensive stage, maintenance after first-line therapy
Observation
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jett et al. 1994 (NCCTG 86-20-51) | 1987-1990 | Phase III (C) | IFN gamma | Did not meet primary endpoint of OS |
van Zandwijk et al. 1997 (EORTC 0883) | 1989-1993 | Phase III (C) | IFN gamma | Did not meet primary endpoint of OS |
Hanna et al. 2002 | 1993-1998 | Phase III (C) | Etoposide | Might have inferior OS |
Schiller et al. 2001 (ECOG E7593) | 1995-1999 | Phase III (C) | Topotecan | Did not meet primary endpoint of OS50% |
Ready et al. 2015 (CALGB 30504) | 2007-2011 | Randomized Phase II (C) | Sunitinib | Seems to have inferior PFS |
Santo et al. 2019 (G04.2011) | 2012-2016 | Phase III (C) | Lanreotide | Did not meet primary endpoint of PFS |
No further treatment.
Biomarker eligibility criteria
- G04.2011: Somatostatin receptor positivity at diagnosis
Preceding treatment
- ECOG E7593: Cisplatin & Etoposide x 4
- CALGB 30504: Carboplatin & Etoposide or Cisplatin & Etoposide for 4 to 6 cycles
- G04.2011: Carboplatin & Etoposide or Cisplatin & Etoposide
References
- NCCTG 86-20-51: Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321-6. link to original article PubMed
- EORTC 0883: van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G; EORTC Lung Cancer Cooperative Group. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997 Oct;33(11):1759-66. link to original article PubMed
- ECOG E7593: Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. link to original article PubMed
- Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. link to original article PubMed
- CALGB 30504: Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. link to original article link to PMC article contains verified protocol PubMed NCT00453154
- G04.2011: Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer). Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer. 2019 Aug;134:121-126. Epub 2019 Jun 11. link to original article PubMed EudraCT 2011-005730-20
Placebo
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Shepherd et al. 2002 | 1997-2000 | Phase III (C) | Marimastat | Did not meet primary endpoint of OS |
No further antineoplastic treatment.
References
- Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B; NCIC CTG; EORTC. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9. link to original article PubMed
Relapsed or refractory disease
Best supportive care
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
O'Brien et al. 2006 | 2000-2004 | Phase III (C) | Oral topotecan | Seems to have inferior OS |
No active antineoplastic treatment.
References
- O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec 1;24(34):5441-7. link to original article contains verified protocol PubMed